Business
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
SAN DIEGO, January 30, 2026--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
About this update from Ipsen Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3600,"height":1417,"url":"https://media.zenfs.com/en/business-wire.com/17fd6047b10811de8d91ec3ceaebfeef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nkzvJXWpR6l9tapA7n4axQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/17fd6047b10811de8d91ec3ceaebfeef","width":960,"height":378},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NR0hUoFJSwRaiFw3MnI2Mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/17fd6047b10811de8d91ec3ceaebfeef","width":1200,"height":472}},"lazy":false},{"type":"text","content":"- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, January 30, 2026--(BUSINESS WIRE)--Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.","length":402,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Ipsen has obtained an exclusive option to license the program globally following successful drug candidate nomination. Upon exercise of the option, Ipsen would assume responsibility for global development and commercialization.","length":261,"tagName":"p"},{"type":"text","content":""We are delighted to join forces with Origami whose pioneering work in developing protein degraders targeting genetic neurodegenerative diseases represents a powerful new frontier in rare neuroscience," said Steve Glyman, SVP and Head of Neuroscience Research & Development, Ipsen. "Their approach aligns seamlessly with Ipsen’s strong rare neuroscience heritage and expertise in small‑molecule innovation, enabling us to advance first‑ and best‑in‑class therapies for people living with debilitating conditions where treatment options remain limited."","length":576,"tagName":"p"},{"type":"text","content":""T...